Cargando…

Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease

BACKGROUND: Chagas disease is due to the parasite Trypanosoma cruzi, a protist disseminated by a Triatome vector. This disease is endemic to Latin America and considered by WHO as one of the 17 world’s neglected diseases. In Europe and in North America, imported cases are also detected, due to migra...

Descripción completa

Detalles Bibliográficos
Autores principales: Granjon, Elodie, Dichtel-Danjoy, Marie-Laure, Saba, Esber, Sabino, Ester, Campos de Oliveira, Lea, Zrein, Maan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818036/
https://www.ncbi.nlm.nih.gov/pubmed/27035146
http://dx.doi.org/10.1371/journal.pntd.0004596
_version_ 1782424960497614848
author Granjon, Elodie
Dichtel-Danjoy, Marie-Laure
Saba, Esber
Sabino, Ester
Campos de Oliveira, Lea
Zrein, Maan
author_facet Granjon, Elodie
Dichtel-Danjoy, Marie-Laure
Saba, Esber
Sabino, Ester
Campos de Oliveira, Lea
Zrein, Maan
author_sort Granjon, Elodie
collection PubMed
description BACKGROUND: Chagas disease is due to the parasite Trypanosoma cruzi, a protist disseminated by a Triatome vector. This disease is endemic to Latin America and considered by WHO as one of the 17 world’s neglected diseases. In Europe and in North America, imported cases are also detected, due to migration of population outside of the endemic region. Diagnosis of T. cruzi infection is usually made indirectly by the detection of specific antibodies to T. cruzi antigens. Following initial diagnostic evaluation or screening test (qualifying or discarding blood donation), a confirmation test is performed for samples initially reactive. The test presented in this study aims at the confirmation/refutation of the infectious status of human blood samples and will permit taking appropriate clinical measures. METHODOLOGY/PRINCIPAL FINDINGS: We designed a novel array of twelve antigens and printed these antigens onto 96-well plates. We tested 248 positive samples T. cruzi, 94 unscreened blood donors’ samples from non-endemic area, 49 seronegative blood donors, 7 false-positive and 3 doubtful samples. The observed reactivities were analyzed to propose a decision-tree algorithm that correctly classifies all the samples, with the potential to discriminate false-positive results and sticky samples. We observed that antibodies levels (Sum of all antigens) was significantly higher for PCR positive than for PCR negative samples in all studied groups with Multi-cruzi. CONCLUSION/SIGNIFICANCE: The results described in this study indicate that the Multi-cruzi improves the serological confirmation of Chagas disease. Moreover the “sum of all antigens” detected by Multi-cruzi could reflect parasitemia level in patients–like PCR signals does—and could serve as an indicator of parasite clearance in longitudinal follow-ups. Validation of this assay is still required on an independent large collection of well characterized samples including typical false-reactive samples such as Leishmaniasis.
format Online
Article
Text
id pubmed-4818036
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48180362016-04-19 Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease Granjon, Elodie Dichtel-Danjoy, Marie-Laure Saba, Esber Sabino, Ester Campos de Oliveira, Lea Zrein, Maan PLoS Negl Trop Dis Research Article BACKGROUND: Chagas disease is due to the parasite Trypanosoma cruzi, a protist disseminated by a Triatome vector. This disease is endemic to Latin America and considered by WHO as one of the 17 world’s neglected diseases. In Europe and in North America, imported cases are also detected, due to migration of population outside of the endemic region. Diagnosis of T. cruzi infection is usually made indirectly by the detection of specific antibodies to T. cruzi antigens. Following initial diagnostic evaluation or screening test (qualifying or discarding blood donation), a confirmation test is performed for samples initially reactive. The test presented in this study aims at the confirmation/refutation of the infectious status of human blood samples and will permit taking appropriate clinical measures. METHODOLOGY/PRINCIPAL FINDINGS: We designed a novel array of twelve antigens and printed these antigens onto 96-well plates. We tested 248 positive samples T. cruzi, 94 unscreened blood donors’ samples from non-endemic area, 49 seronegative blood donors, 7 false-positive and 3 doubtful samples. The observed reactivities were analyzed to propose a decision-tree algorithm that correctly classifies all the samples, with the potential to discriminate false-positive results and sticky samples. We observed that antibodies levels (Sum of all antigens) was significantly higher for PCR positive than for PCR negative samples in all studied groups with Multi-cruzi. CONCLUSION/SIGNIFICANCE: The results described in this study indicate that the Multi-cruzi improves the serological confirmation of Chagas disease. Moreover the “sum of all antigens” detected by Multi-cruzi could reflect parasitemia level in patients–like PCR signals does—and could serve as an indicator of parasite clearance in longitudinal follow-ups. Validation of this assay is still required on an independent large collection of well characterized samples including typical false-reactive samples such as Leishmaniasis. Public Library of Science 2016-04-01 /pmc/articles/PMC4818036/ /pubmed/27035146 http://dx.doi.org/10.1371/journal.pntd.0004596 Text en © 2016 Granjon et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Granjon, Elodie
Dichtel-Danjoy, Marie-Laure
Saba, Esber
Sabino, Ester
Campos de Oliveira, Lea
Zrein, Maan
Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease
title Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease
title_full Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease
title_fullStr Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease
title_full_unstemmed Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease
title_short Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease
title_sort development of a novel multiplex immunoassay multi-cruzi for the serological confirmation of chagas disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818036/
https://www.ncbi.nlm.nih.gov/pubmed/27035146
http://dx.doi.org/10.1371/journal.pntd.0004596
work_keys_str_mv AT granjonelodie developmentofanovelmultipleximmunoassaymulticruzifortheserologicalconfirmationofchagasdisease
AT dichteldanjoymarielaure developmentofanovelmultipleximmunoassaymulticruzifortheserologicalconfirmationofchagasdisease
AT sabaesber developmentofanovelmultipleximmunoassaymulticruzifortheserologicalconfirmationofchagasdisease
AT sabinoester developmentofanovelmultipleximmunoassaymulticruzifortheserologicalconfirmationofchagasdisease
AT camposdeoliveiralea developmentofanovelmultipleximmunoassaymulticruzifortheserologicalconfirmationofchagasdisease
AT zreinmaan developmentofanovelmultipleximmunoassaymulticruzifortheserologicalconfirmationofchagasdisease